Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $40.50 Consensus Price Target from Analysts

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) have been assigned an average recommendation of "Buy" from the eight analysts that are currently covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $40.50.

Several research firms have weighed in on PLRX. Leerink Partnrs upgraded Pliant Therapeutics to a "strong-buy" rating in a report on Monday, September 9th. HC Wainwright reiterated a "buy" rating and set a $38.00 price objective on shares of Pliant Therapeutics in a report on Friday, November 8th. Finally, Leerink Partners assumed coverage on Pliant Therapeutics in a research note on Monday, September 9th. They set an "outperform" rating and a $33.00 target price for the company.

Pliant Therapeutics Trading Up 1.0 %

Shares of NASDAQ PLRX traded up $0.13 during midday trading on Monday, reaching $13.34. 819,922 shares of the stock were exchanged, compared to its average volume of 470,762. Pliant Therapeutics has a 12 month low of $10.22 and a 12 month high of $19.62. The company has a market capitalization of $811.79 million, a price-to-earnings ratio of -3.99 and a beta of 1.05. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.26 and a quick ratio of 10.26. The business has a 50-day simple moving average of $14.08 and a two-hundred day simple moving average of $12.83.

Institutional Investors Weigh In On Pliant Therapeutics

Several institutional investors have recently bought and sold shares of the company. Great Point Partners LLC grew its stake in shares of Pliant Therapeutics by 42.4% during the 2nd quarter. Great Point Partners LLC now owns 2,636,864 shares of the company's stock worth $28,346,000 after acquiring an additional 785,000 shares in the last quarter. Candriam S.C.A. grew its position in Pliant Therapeutics by 52.0% in the second quarter. Candriam S.C.A. now owns 833,216 shares of the company's stock valued at $8,957,000 after purchasing an additional 285,216 shares in the last quarter. Renaissance Technologies LLC increased its stake in Pliant Therapeutics by 233.8% in the 2nd quarter. Renaissance Technologies LLC now owns 253,369 shares of the company's stock valued at $2,724,000 after buying an additional 177,469 shares during the last quarter. Checkpoint Capital L.P. lifted its position in Pliant Therapeutics by 63.7% during the 3rd quarter. Checkpoint Capital L.P. now owns 380,000 shares of the company's stock worth $4,260,000 after buying an additional 147,800 shares in the last quarter. Finally, Rice Hall James & Associates LLC acquired a new position in shares of Pliant Therapeutics during the 2nd quarter worth about $1,372,000. Institutional investors own 97.30% of the company's stock.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.